Search by Drug Name or NDC
NDC 00078-0364-05 Lotrel 10; 20 mg/1; mg/1 Details
Lotrel 10; 20 mg/1; mg/1
Lotrel is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE.
MedlinePlus Drug Summary
The combination of amlodipine and benazepril is used to treat high blood pressure. Amlodipine is in a class of medications called calcium channel blockers. It works by relaxing the blood vessels so the heart does not have to pump as hard. Benazepril is in a class of medications called angiotensin-converting enzyme (ACE) inhibitors. It works by decreasing certain chemicals that tighten the blood vessels, so blood flows more smoothly. High blood pressure is a common condition and when not treated, can cause damage to the brain, heart, blood vessels, kidneys and other parts of the body. Damage to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vision, and other problems. In addition to taking medication, making lifestyle changes will also help to control your blood pressure. These changes include eating a diet that is low in fat and salt, maintaining a healthy weight, exercising at least 30 minutes most days, not smoking, and using alcohol in moderation.
Related Packages: 00078-0364-05Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Amlodipine and Benazepril
Product Information
| NDC | 00078-0364 |
|---|---|
| Product ID | 0078-0364_218c693b-b915-4231-9d73-751898db6b72 |
| Associated GPIs | 36991502200150 |
| GCN Sequence Number | 050519 |
| GCN Sequence Number Description | amlodipine besylate/benazepril CAPSULE 10 MG-20MG ORAL |
| HIC3 | A4K |
| HIC3 Description | ACE INHIBITOR-CALCIUM CHANNEL BLOCKER COMBINATION |
| GCN | 17604 |
| HICL Sequence Number | 010041 |
| HICL Sequence Number Description | AMLODIPINE BESYLATE/BENAZEPRIL HCL |
| Brand/Generic | Brand |
| Proprietary Name | Lotrel |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | amlodipine besylate and benazepril hydrochloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 10; 20 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE |
| Labeler Name | Novartis Pharmaceuticals Corporation |
| Pharmaceutical Class | Angiotensin Converting Enzyme Inhibitor [EPC], Angiotensin-converting Enzyme Inhibitors [MoA], Calcium Channel Antagonists [MoA], Calcium Channel Blocker [EPC], Cytochrome P450 3A Inhibitors [MoA], Decreased Blood Pressure [PE], Dihydropyridine Calcium Ch |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA020364 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00078-0364-05 (00078036405)
| NDC Package Code | 0078-0364-05 |
|---|---|
| Billing NDC | 00078036405 |
| Package | 100 CAPSULE in 1 BOTTLE (0078-0364-05) |
| Marketing Start Date | 1995-03-03 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |